The insider selling is immaterial and likely post-earnings routine activity. Monitor for any larger open-market sales by C-suite executives, but this cluster alone warrants no trading action.
INCY drugs
INCY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 10 $121.55entry
- T+1 · 3mo ago −0.39%α −0.08% · $121.07
- T+5 · 3mo ago +1.60%α +1.65% · $123.50
- T+20 · 2mo ago +2.34%α +3.26% · $124.40
- T+60 · 13d ago −3.26%α −0.84% · $117.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two senior R&D executives at Incyte (President and Chief Scientific Officer) sold a combined $2.18M of stock in the week following the Q2 earnings beat. The sales are trivial relative to Incyte's $24B market cap (0.009%) and likely reflect routine post-earnings window rebalancing and derivative exercise coverage, not a bearish signal.
Key Financial Metrics
Key Facts
- Pablo J. Cagnoni (President, Global Head of R&D) sold $1.90M on 2026-07-31; Patrick A. Mayes (EVP & Chief Scientific Officer) sold ~$274K on 2026-08-05 after exercising options
- Total cluster value: $2.18M (0.009% of $24B market cap)
- Cluster occurred 3–10 days after Incyte's Q2 2026 earnings (8-K filed 7/28), which beat consensus but included a one-time CMS settlement benefit
- Mayes' sales corresponded with derivative exercises at $105–$106 strike, suggesting tax- or exercise-cost coverage
Financial Impact
Trivial insider selling, $2.18M total vs $24B market cap (0.009%). No material impact.
Risk Factors
- Larger insider sales in coming weeks could shift sentiment
- Q2 earnings beat was partly one-time; future quarters may not sustain the same earnings power
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-INCY-1786132957799 |
Track record
18 reports on INCY
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +23.70% at T+60 after the Jun 8, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $118.50 Now $120.27 +1.49% settles Feb 16
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $123.09 Now $120.27 −2.29% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $119.45 Now $120.27 +0.69% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $120.97 Now $120.27 −0.58% settles Feb 11
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $122.27 Now $120.27 −1.64% settles Feb 9
- Nov 6, 202610d ago 144 Neutral 4/10 Entry $121.89 Now $120.27 −1.33% settles Feb 5
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $122.85 Now $120.27 −2.10% settles Feb 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $116.80 Now $120.27 +2.97% settles Jan 27
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $115.71 Now $120.27 +3.94% settles Jan 21
- Aug 14, 202613w ago Insider Cluster Bearish 4/10 Entry $123.50 to $120.30 Now $120.27 +2.62% ▲ +2.59% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers